Acella Pharmaceuticals is recalling two lots of its thyroid drugs due to subpotency, the Alpharetta, Ga.-based drugmaker said Sept. 17. 

Moderna said Sept. 17 that it will begin developing a seasonal flu vaccine. 

Pfizer released the protocol for its phase 3 COVID-19 vaccine trial Sept. 17, shortly after Moderna did the same, The New York Times reported. 

The woman who experienced a severe adverse reaction after receiving a COVID-19 vaccine while participating in AstraZeneca's U.K. trial had transverse myelitis, according to an internal safety report obtained by CNN.

Moderna released a 135-page document Sept. 17 that details how it is conducting its phase 3 COVID-19 vaccine trial and says how safety and efficacy will be determined. 

Eli Lilly and Amgen are uniting to boost manufacturing capacity for Eli Lilly's experimental COVID-19 drugs, they said Sept. 17. 

While prices for most medical goods and services are rising, drug prices are increasing the fastest, according to a Sept. 17 GoodRx report.

Moderna could know if its COVID-19 vaccine is safe and effective within a few weeks, according to a Sept. 17 report from The Boston Globe.

CVS Health said Sept. 17 it is doubling the number of COVID-19 test sites it operates, bringing the total to more than 4,000 by mid-October. 

Walgreens launched the Walgreens Test & Protect program Sept. 17, designed to aid businesses in their COVID-19 work plans and strategies. 

The rising cost of Gilead's Truvada may be a key factor in why the HIV prevention drug has not been widely used, according to an analysis published in the Annals of Internal Medicine. 

San Diego-based Scripps Health has created a COVID-19 vaccine committee to recommend vaccines to offer its patients, employees and physicians. 

A monoclonal antibody drug being developed by Eli Lilly helped the virus leave COVID-19 patients's systems sooner, according to interim analysis of an ongoing study assessing the drug's effectiveness in treating the disease.

CVS Health said Sept. 16 that it is investing $13.7 million to help renovate 230 low-income housing apartments in Columbus, Ohio, as part of its commitment to invest nearly $600 million over five years to address racial inequality and social determinants of health in Black communities. 

An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors. 

Americans are apprehensive about placing their full trust in both the FDA and drugmakers, according to the latest findings from the Axios-Ipsos Coronavirus Index.

A bipartisan group of 243 members of the House of Representatives sent a letter to HHS Secretary Alex Azar Sept. 14 urging him to use his authority to stop drugmakers from blocking safety-net hospitals' access to 340B discounts. 

An official from the National Institutes of Health told Kaiser Health News Sept. 14 that the agency is "very concerned" about a pause in AstraZeneca's COVID-19 vaccine trial due to an adverse reaction in a U.K. patient. 

Gilead is studying new ways to use remdesivir as a COVID-19 treatment, CEO Daniel O'Day said Sept. 14 during a CNBC interview.

Eli Lilly said Sept. 14 that its rheumatoid arthritis drug, Olumiant, in combination with remdesivir shortened recovery time by about a day for COVID-19 patients in comparison to those treated with just remdesivir.